CASE REPORT

REVISED Case Report: Dilated cardiomyopathy with biventricular thrombus secondary to impaired coagulation in a patient with HIV [version 2; peer review: 2 approved]

Chetan Brahma Kammari ¹, Suhasini Rallabandi², Harsha Rallabandi³,
Subba Rao Daggubati ⁴, Sreedhar Adapa⁵, Srikanth Naramala⁶,
Venu Madhav Konala ⁷

¹Department of Internal Medicine, Cape Fear Valley Hospital, Fayetteville, NC, 28304, USA

²Department of Internal Medicine, Mery Hospital Joplin, Joplin, MO, 64804, USA

³Gandhi Medical College, Secunderabad, Telangana, 500003, India

⁴Wise Health System, Decatur, TX, 76234, USA

⁵Department of Internal Medicine, Division of Nephrology, Kaweah Delta Medical Center, Visalia, CA, 93291, USA

⁶Department of Internal Medicine, Division of Rheumatology, Adventist Medical Center, Hanford, CA, 93230, USA

⁷Department of Internal Medicine, Division of Medical Oncology, Ashland Bellefonte Cancer Center, Ashland, KY, 41101, USA

v2 First published: 15 Jun 2020, 9:610
<https://doi.org/10.12688/f1000research.24016.1>

Latest published: 07 Jul 2020, 9:610
<https://doi.org/10.12688/f1000research.24016.2>

Abstract

Human immunodeficiency virus (HIV) infection is a known hypercoagulable state with venous thromboembolism with a high mortality rate compared to the general population. The homeostatic balance in HIV infected patients improves with treatment compared to those who are not. A decreased hypercoagulable state noted by low levels of Von Willebrand factor, factor VIII and d-dimer levels along with higher protein C and S activity in patients on treatment suggests that hypercoagulable state is partially correctable with highly active antiretroviral therapy. HIV with heart muscle involvement can present as myocarditis or as dilated cardiomyopathy with left or right ventricular dysfunction. Here we present a case of a 57-year-old man with a known history of HIV infection, noncompliant with medical therapy presenting with dilated cardiomyopathy with biventricular thrombi with reduced protein C, protein S, and Antithrombin III levels.

Keywords

HIV, Hypercoagulable, Ventricular, thrombus, protein c, protein s, antithrombin 3

Open Peer Review

Approval Status

	1	2
version 2		
(revision)		
07 Jul 2020		
version 1		
15 Jun 2020		

1. **Raju Vaddepally** , Yuma Regional Medical Center, Yuma, USA

2. **Satyanarayana Vaidya** , Emory University, Atlanta, USA

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Chetan Brahma Kammari (cbkammari@gmail.com)

Author roles: **Kammari CB:** Conceptualization, Data Curation, Investigation, Resources, Writing – Original Draft Preparation, Writing – Review & Editing; **Rallabandi S:** Conceptualization, Data Curation, Investigation, Resources; **Rallabandi H:** Data Curation, Investigation, Writing – Original Draft Preparation; **Daggubati SR:** Project Administration, Resources, Supervision; **Adapa S:** Investigation, Project Administration, Supervision; **Naramala S:** Investigation, Project Administration, Supervision; **Konala VM:** Supervision, Validation, Visualization, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2020 Kammari CB *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Kammari CB, Rallabandi S, Rallabandi H *et al.* **Case Report: Dilated cardiomyopathy with biventricular thrombus secondary to impaired coagulation in a patient with HIV [version 2; peer review: 2 approved]** F1000Research 2020, 9:610 <https://doi.org/10.12688/f1000research.24016.2>

First published: 15 Jun 2020, 9:610 <https://doi.org/10.12688/f1000research.24016.1>

REVISED Amendments from Version 1

1. We have updated the first paragraph of the case report as suggested by the reviewer and removed any redundant text.
2. We also added comments at the end of conclusion section of the article as below.

"We think that low protein C, low protein S levels, and antithrombin-III deficiency could contribute to thrombus formation if truly positive in addition to the risk factors discussed above. However, it could represent a thrombus consuming the factors, and they will be repeated six months to confirm it."

Any further responses from the reviewers can be found at the end of the article

Introduction

Human immunodeficiency virus (HIV) infection is a well-known hypercoagulable state associated with venous thromboembolism with high mortality risk compared to the general population^{1,2}. HIV with heart muscle involvement can present as myocarditis or as dilated cardiomyopathy with left or right ventricular dysfunction³. Here we present a case of a patient infected with HIV presenting with dilated cardiomyopathy with biventricular thrombi secondary to reduced protein C, protein S, and antithrombin III levels. On review of the literature, we were able to find only one similar presentation where a patient with HIV has cardiomyopathy with biventricular thrombosis⁴.

Case report

The patient is a 57-year-old Caucasian male with a known past medical history of the human immunodeficiency virus (HIV) non-compliant with medical therapy and hyperlipidemia, who presented to the emergency department with shortness of breath, hypoxia with oxygen saturation of 70%, pleuritic chest pain and a syncopal episode with fall. The patient denied any significant family, surgical, or social history. He was treated for pneumonia six weeks before presentation with antibiotics, and since then, he has been experiencing exertional dyspnea. Patient unable to do his activities of daily living due to exertional dyspnea. The patient denied orthopnea or paroxysmal nocturnal dyspnea. He had a syncopal episode at home with fall resulting in left pleuritic chest pain. The patient admitted that he had previous syncope episodes that occur with little or no warning signs except for mild dizziness before passing out. The physical examination was significant for chest wall tenderness with a normal cardiorespiratory exam.

Laboratory findings showed mildly elevated troponin. An echocardiogram demonstrated biventricular dilatation with ejection fraction (EF) of 30% and compelling evidence for the presence of thrombus in the apex of both ventricles and free wall of the right ventricle (as shown in Figure 1–Figure 4). Echocardiogram did not demonstrate any spontaneous echo contrast, suggesting severely diminished ejection fraction and stagnation of blood flow. Orthostatic vitals were normal, and the patient did not experience any arrhythmias on telemetry ruling them out as a cause for syncope. Syncope was later presumed to be likely secondary to a low flow state from reduced EF. The patient denied any prior history of deep vein thrombosis, transient ischemic attack,

or stroke. CT chest with contrast did not show any evidence of pulmonary embolism but showed diffuse cardiomegaly (Figure 5 and Figure 6). Given the presence of biventricular thrombus, the patient was evaluated for the hypercoagulable state. Results showed low Protein C, protein S, and antithrombin III levels. Factor V Leiden and lupus anticoagulant were normal. The laboratory findings are summarized in Table 1.

Cardiology initially considered cardiac catheterization to delineate the patient's coronary anatomy for the potential need for revascularization, but instead decided to perform stress myocardial perfusion study to prevent thromboembolic events and strokes that can be associated with the procedure. The nuclear stress test was negative for reversible ischemia. There was no evidence of fixed defects on the stress test, suggesting no evidence of prior myocardial infarction or scar tissue within the myocardium. The patient was started on Lasix 20mg oral daily, metoprolol succinate 25mg oral daily, and low-dose Lisinopril 2.5mg oral daily. Novel anticoagulants (NOACs) are not recommended for

Figure 1. Echocardiogram (Apical 2 chamber view) showing dilated left ventricle showing apical thrombus.

Figure 2. Echocardiogram (Apical 2 chamber view) showing dilated left ventricle with apical thrombus measurements.

Figure 3. Echocardiogram (Apical 4 chamber view) showing dilated right ventricle with apical thrombus.

Figure 4. Echocardiogram (Apical 4 chamber view) showing dilated right ventricle with apical thrombus measurements.

mural thrombus; therefore, the patient was started on a therapeutic dose of low molecular weight heparin 60mcg subcutaneous twice daily and bridged with warfarin 5mg oral daily. Heparin was discontinued once his International Normalized Ratio (INR) was therapeutic. One week after the admission, the patient was ready to be discharged. His symptoms had significantly improved with no further syncopal episodes or exertional dyspnea. His ambulatory oxygen saturations were normal on room air. The patient was advised to follow up with infectious diseases to initiate highly active antiretroviral therapy (HAART) therapy for his HIV, cardiology and hematology for continued care.

Discussion

HIV infection is a well-known hypercoagulable state with a frequency of thrombotic events recognized in the range of

Figure 5. CT of chest with IV contrast showing left ventricular and right ventricular enlargement.

Figure 6. CT of chest without contrast showing left ventricular and right ventricular enlargement.

0.19% to 7.63% per year¹. Compared to the general population of the same age, the risk of arterial and venous thrombosis in HIV infected patients is increased two to tenfold. One possible explanation could be due to the presence of multiple comorbidities and baseline increased inflammatory/hypercoagulable state. Risk factors like low CD4 cell count, especially in the presence of clinical acute immunodeficiency syndrome (AIDS), protein S deficiency, and protein C deficiency, have demonstrated the strongest association with venous thromboembolism.

Table 1. Summary of laboratory findings.

	Patient value (normal range)
Sodium	132 mol/L (136–145)
Glucose	64 mg/dl (74–99)
Blood Urea Nitrogen	31 mg/dl (6–20)
Creatinine	1.09 mg/dl (0.7–1.20)
White Blood Cell Count	13.4 k/ul (4.5–0.8)
Absolute Neutrophil Count	8.65 k/ul (1.5–7)
Hemoglobin	16.5 g/dl (13.5–18.0)
Platelets	346 k/ul (150–450)
HIV Antibodies	Positive
CD4 T Cell Count	815cells/mcl (365–1437)
CD8 T Cell Count	614 cells/mcl (117–846)
CD4/CD8 Ratio	1.3 (>0.9)
Hepatitis A Antibody	Negative
Hepatitis B Surface and Core Antigen	Negative
Hepatitis C Antibody	Negative
Alkaline Phosphatase	152 u/l (40–129)
Aspartate Aminotransferase	270 u/l (10–50)
Alanine Aminotransferase	458 u/l (10–50)
NT pro B-type Natriuretic Peptide	4485 pg/ml (0–125)
Troponin (0 hr, 6 hr, 12 hr)	89, >90, >106 ng/l (<15)
Protein C Activity	46% (70–140)
Protein S Activity	38% (45–125)
Antithrombin III Activity	77% (80–120)
Factor V Leiden	Negative
Lupus Anticoagulant	Negative
Anti-Cardiolipin Antibodies	Normal
Anti-Beta 2 Glycoprotein Antibodies	Normal
Prothrombin Gene Mutation	Negative

Other less significant and controversial risk factors include protease inhibitor therapy, opportunistic infections, and positive antiphospholipid antibodies, including anticardiolipin antibodies and lupus anticoagulant^{1,5}. Thrombophilic abnormalities in total platelet count, protein C, and S activity are directly correlated to CD4 count⁶, and their frequency increases as the patient progresses to AIDS⁷. HIV infection with venous thromboembolism has a high mortality rate compared to the general population².

The homeostatic balance in HIV-infected patients varies if they are on HAART therapy vs. not being on treatment. The indicators of hypercoagulable state like the activity of the Von Willebrand factor, levels of Factor VIII, and D dimer are lower in patients on treatment. Also, anticoagulant proteins like protein C and

S activity are higher in patients on therapy, suggesting the hypercoagulable state is partially correctable with HAART. Although patients on HAART therapy have a lower prevalence of coagulation abnormalities, many show the persistent procoagulant state as evident by increased endothelial cell activation and high APCsr when compared to the general population. Continued coagulation markers abnormalities have been observed in HIV-infected individuals before and after the initiation of HAART⁸. Even patients who are newly started on HAART therapy showed marked improvement in the coagulation profile but still different from the general population, indicating a persistent abnormal homeostatic balance⁹. In addition, it has been previously observed that most HIV positive patients with low protein S levels also had mutations in exon 15 of PROS 1 gene warranting further investigation¹⁰.

Cardiac dysfunction in HIV-infected patients evidenced by congestive heart failure is a well-documented finding. Even in asymptomatic HIV patients, an echocardiographic and echo-doppler examination has shown evidence of early signs of impaired systolic and diastolic function, suggesting an early involvement of the heart in HIV disease¹¹. Cardiomyopathy associated with HIV may be related to the autoimmune process induced by HIV in conjugation with other cardio tropic virus or could be direct action on the heart muscle¹². It is shown that the incidence of dilated cardiomyopathy in HIV is 17.6%¹³. HIV with heart muscle involvement can present as myocarditis or dilated cardiomyopathy with left or right ventricular dysfunction, the pathogenesis of which seems to relate to the coinfection with other infectious agents³. Isolated right and left heart dysfunction have no direct correlation to the CD4 count and does not carry adverse prognostic implications¹⁴.

Long term anticoagulation may be beneficial in HIV infected patients to prevent future thromboembolic events as most of the contributing risk factors are often irreversible. Since there is a possibility of interactions between warfarin and antiretroviral therapy, health care providers should be watchful of consequent dangerously high or low INRs when giving warfarin to patients undergoing antiretroviral therapy¹. It is shown that newer anticoagulants can be used with antiretroviral therapy without any noticeable interactions¹⁵.

Conclusion

In our patient, a bi-ventricular thrombus is likely the result of the hypercoagulable state along with severe ventricular dysfunction with dilated cardiomyopathy due to underlying HIV infection. Systemic or pulmonary embolization was not seen in our patient, as reported in the past as an associated finding¹⁶. Physicians caring for patients with HIV should always consider thrombotic and thromboembolic events in the differential besides known malignancies and opportunistic infections when treating patients with unexplained dyspnea or hypoxia, especially in young males.

We think that low protein C, low protein S levels, and antithrombin-III deficiency could contribute to thrombus formation if truly positive in addition to the risk factors discussed above. However, it could represent a thrombus consuming the factors, and they will be repeated six months to confirm it.

Consent

Written informed consent for the publication of the case report and any associated images was obtained from the patient.

Data availability

All data underlying the results are available as part of the article and no additional source data are required.

References

- Bibas M, Biava G, Antinori A: **HIV-associated venous thromboembolism**. *Mediterr J Hematol Infect Dis*. 2011; 3(1): e2011030.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Fultz SL, McGinnis KA, Skanderson M, *et al.*: **Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans**. *Am J Med*. 2004; 116(6): 420–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Khunnawat C, Mukerji S, Havlicek D Jr, *et al.*: **Cardiovascular manifestations in human immunodeficiency virus-infected patients**. *Am J Cardiol*. 2008; 102(5): 635–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Nkoke C, Kuate LM, Luchuo EB, *et al.*: **Biventricular thrombi in dilated cardiomyopathy in a patient with human immunodeficiency virus infection: a case report**. *BMC Res Notes*. 2015; 8(1): 168.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kiser KL, Badowski ME: **Risk factors for venous thromboembolism in patients with human immunodeficiency virus infection**. *Pharmacotherapy*. 2010; 30(12): 1292–302.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Khare S, Kushwaha R, Kumar A, *et al.*: **Prothrombotic state in HIV: A study on protein C, protein S, homocysteine and correlation with CD4 counts**. *Indian J Med Microbiol*. 2018; 36(2): 201–206.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Lijfering WM, Sprenger HG, Georg RR, *et al.*: **Relationship between progression to AIDS and thrombophilic abnormalities in HIV infection**. *Clin Chem*. 2008; 54(7): 1226–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Jong E, Louw S, Meijers JC, *et al.*: **The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy**. *AIDS Patient Care STDS*. 2009; 23(12): 1001–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Jong E, Louw S, Gorp ECM: **The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals**. *Thromb Haemost*. 2010; 104(6): 1228–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Di Stefano M, D'Andrea G, Zoboli F, *et al.*: **Preliminary Data From the Study of Coagulative Profile of HIV Infected Individuals Suggest a Role For Point Mutations in the Gene in Protein S Deficiency in Individuals Undergoing Highly Antiretroviral Therapy**. *Open AIDS J*. 2018; 12: 6–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Barbaro G, Barbarini G, Di Lorenzo G: **Early impairment of systolic and diastolic function in asymptomatic HIV-positive patients: a multicenter echocardiographic and echo-doppler study**. *AIDS Res Hum Retroviruses*. 1996; 12(16): 1559–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Barbaro G, Di Lorenzo G, Grisorio B, *et al.*: **Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study**. *AIDS Res Hum Retroviruses*. 1998; 14(12): 1071–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Jain N, Reddy DH, Verma SP, *et al.*: **Cardiac abnormalities in HIV-positive patients: results from an observational study in India**. *J Int Assoc Provid AIDS Care*. 2014; 13(1): 40–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Currie PF, Jacob AJ, Foreman AR, *et al.*: **Heart muscle disease related to HIV infection: prognostic implications**. *BMJ*. 1994; 309(6969): 1605–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Natarajan P, Joolhar F, Thangarasu S, *et al.*: **Embolizing Massive Right Atrial Thrombus in a HIV-Infected Patient**. *J Investig Med High Impact Case Rep*. 2018; 6: 2324709618802871.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Missault L, Koch A, Colardyn F, *et al.*: **Biventricular thrombi in dilated cardiomyopathy: massive simultaneous pulmonary and systemic embolisation**. *Eur Heart J*. 1994; 15(5): 713–4.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 14 July 2020

<https://doi.org/10.5256/f1000research.27810.r66622>

© 2020 Vaidya S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Satyanarayana Vaidya

Emory University, Atlanta, GA, USA

The authors have addressed most of major concerns in the case report. The case report emphasizes the importance of considering increased thrombogenicity in HIV patients.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Nephrology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 08 July 2020

<https://doi.org/10.5256/f1000research.27810.r66621>

© 2020 Vaddepally R. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Raju Vaddepally

Department of Hematology/Medical Oncology, Yuma Regional Medical Center, Yuma, AZ, USA

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Hematology, Medical Oncology Thoracic and head and neck medical Oncology, Immunotherapy, Targeted therapy, Precision Medicine.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 01 July 2020

<https://doi.org/10.5256/f1000research.26492.r64869>

© 2020 Vaidya S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Satyanarayana Vaidya

Emory University, Atlanta, GA, USA

Authors have done a commendable job in writing a detailed case report depicting Increased thrombogenicity and a low blood flow state in HIV a infected patient as primary mechanisms of the virchow triad causing biventricular thrombosis. The tables, figures provide great deal of detailed information regarding the location of thrombus.

I would like to highlight certain important points and would encourage the inclusion of those in the case report

1. The low flow state due to cardiomyopathy seems to have been a primary mechanism here causing biventricular thrombosis. If patient had a transesophageal echocardiography to exclude a patent foramen ovale which can result in paradoxical embolism or deep vein assessment with a venous doppler, inclusion of that information would be critical to exclude any possibility of venous thromboembolism
2. Patient seems to have a decent CD4 count of 815 cells/microliter despite being non-compliant with Antiretroviral therapy. Inclusion of HIV viral load would give more information as there is evidence regarding high viral loads and low CD4 counts being related to increased thrombogenicity. In addition, presence of a reasonable CD4 cell count argues against the possibility of HIV associated nephropathy which can cause significant proteinuria causing loss of anticoagulant proteins causing a thrombogenic state. Information regarding protein: creatinine ratio would have evaluated that possibility.
3. One would always make an argument of low protein C, protein S levels being low in the setting of acute thrombosis. Following them after a period of at least 6 months would reveal the true levels and differentiate between true deficiency vs due to consumption due to thrombosis.

Is the background of the case's history and progression described in sufficient detail?

Yes

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?

Partly

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?

Yes

Is the case presented with sufficient detail to be useful for other practitioners?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Nephrology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 02 Jul 2020

Chetan Kammari, Cape Fear Valley Hospital, Fayetteville, USA

We agree with the reviewer's comment that the low flow state due to cardiomyopathy could have contributed, we think it is multifactorial in this patient with low flow state as well as possible protein deficiencies if truly positive contributing to it. Unfortunately, a TEE was not done during that hospitalization.

I agree with the reviewer's comment that low protein C, low protein S, and anti-thrombin deficiency could represent the state of thrombus consuming the factors. It is not 6 months yet and the patient continues to be followed up as an outpatient. Modified in the manuscript.

We thank the reviewer for pointing out normal CD4 count - low CD4 count is one of the risk factors, but there additional risk factors in HIV infected patients like a protein C deficiency, protein S deficiency, antithrombin deficiency, antiphospholipid antibody syndrome, endothelial dysfunction in addition to the traditional risk factors such as obesity, cigarette smoking, hypertension, immobilization. We think that thrombus is multifactorial in this patient. We did not think the patient has HIV-induced nephropathy resulting in nephrotic syndrome - hence it was not investigated further, no protein creatinine ratio was done during the admission.

Competing Interests: None

Reviewer Report 29 June 2020

<https://doi.org/10.5256/f1000research.26492.r64868>

© 2020 Vaddepally R. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Raju Vaddepally

Department of Hematology/Medical Oncology, Yuma Regional Medical Center, Yuma, AZ, USA

This is a very nice case review on alterations in homeostatic mechanism in HIV. I tend to agree that there are inflammatory changes in HIV patients that deranges the the coagulation equilibrium and there are limitations in available literature on what exactly drives the prothrombotic features in such patients.

Having said that in this case, the patient seems to have dilated cardiomyopathy which largely seems to have driven the thrombosis and the case has been very well elaborated with description, pictures, and lab assay. However, the low protein C, S, and Antithrombin evidenced here rather depicts the state of thrombus consuming the factors. It would have been nice if they had follow up lab assay follow on these protein C, S, and Antithrombin and if the numbers continue to remain low after 3-6 months from the time of thrombosis then one could make a strong argument that the coagulation factor deficiencies could have accentuated the thrombosis but it is unclear at this time based on the available labs.

The authors should be commended for ensuring the APAS etiology has been ruled out which would be an important etiology in HIV patients. However, I do suggest trimming the case report content especially in the first paragraph where there is redundancy in non-pertinent information. Overall, I feel this contributes some knowledge to existing data of HIV and hypercoagulability.

Is the background of the case's history and progression described in sufficient detail?

Yes

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?

Yes

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?

Partly

Is the case presented with sufficient detail to be useful for other practitioners?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Hematology, Medical Oncology Thoracic and head and neck medical Oncology, Immunotherapy, Targeted therapy, Precision Medicine.

I confirm that I have read this submission and believe that I have an appropriate level of

expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 02 Jul 2020

Chetan Kammari, Cape Fear Valley Hospital, Fayetteville, USA

I agree with the reviewer's comment that low protein C, low protein S, and anti-thrombin deficiency could represent the state of thrombus consuming the factors. It is not 6 months yet and the patient continues to be followed up as an outpatient. Modified in the manuscript.

Modified in the manuscript as below - We think that low protein C, low protein S levels, and antithrombin-III deficiency could contribute to thrombus formation if truly positive in addition to the risk factors discussed above. However, it could represent a thrombus consuming the factors, and they will be repeated six months to confirm it.

We trimmed the case report content in the first paragraph as advised.

First Paragraph -

The patient is a 57-year-old Caucasian male with a known past medical history of the human immunodeficiency virus (HIV) non-compliant with medical therapy and hyperlipidemia, who presented to the emergency department with shortness of breath, hypoxia with oxygen saturation of 70%, pleuritic chest pain and a syncopal episode with fall. The patient denied any significant family, surgical, or social history. He was treated for pneumonia six weeks before presentation with antibiotics, and since then, he has been experiencing exertional dyspnea. Patient unable to do his activities of daily living due to exertional dyspnea. The patient denied orthopnea or paroxysmal nocturnal dyspnea. He had a syncopal episode at home with fall resulting in left pleuritic chest pain. The patient admitted that he had previous syncope episodes that occur with little or no warning signs except for mild dizziness before passing out. The physical examination was significant for chest wall tenderness with a normal cardiorespiratory exam.

Competing Interests: None

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research